Basilea Pharmaceutica is focused on treating infectious diseases; marketed products are Cresemba (antifungal) and Zevtera (anti-MRSA broad-spectrum antibiotic). In late 2023, it expanded its pipeline to include BAL2062 (antifungal), tonabacase (antibiotic) and Phase III-ready fosmanogepix (antifungal).
There is an ever-increasing need for therapeutic agents that are efficacious against drug-resistant strains of bacteria (eg MRSA) or fungi. Hence the opportunities for Zevtera and Cresemba could be significant.
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Flash note
Adesh Kaul
CFO
David Veitch
CEO
Dung Tran
Investor relations coordinator
Forecast net debt (CHFm)
N/A
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 9.1 | 19.1 | (8.1) |
Relative | 12.7 | 18.5 | (6.0) |
52 week high/low | CHF48.6/CHF32.2 |
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies to address serious fungal and bacterial infections. It continues to make advancements in this specialised segment through the development of opportunistic acquisitions leveraging its anti-infective expertise. Its growth initiatives remain funded through the traction of its commercialised products, Cresemba and Zevtera. FY24 key strategic priorities include the US commercial launch of antibacterial Zevtera and Phase III trial initiation of first-in-class, broad-spectrum antifungal fosmanogepix.
Y/E Dec | Revenue (CHFm) | EBITDA (CHFm) | PBT (CHFm) | EPS (CHFc) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2022A | 147.8 | 19.6 | 12.3 | 104.10 | 38.7 | N/A |
2023A | 157.6 | 20.8 | 10.8 | 89.66 | 44.9 | N/A |
2024E | 187.2 | 34.0 | 28.0 | 233.65 | 17.2 | N/A |
2025E | 209.1 | 37.9 | 32.3 | 269.24 | 14.9 | N/A |